Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13676827 | 1.00 | LMNA (0.56) | LMNAMAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL13533398 | 1.00 | LMNA (0.56) | LMNAMAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL10832911 | 0.85 | LMNA (0.57) | LMNAMAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL4461156 | 0.85 | LMNA (0.54) | LMNAMAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL6636679 | 0.85 | LMNA (0.54) | LMNAMAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL1568390 | 0.85 | LMNA (0.57) | LMNAMAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL12092432 | 0.82 | LMNA (0.51) | LMNAMAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL13210307 | 0.82 | LMNA (0.55) | LMNAMAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL14105818 | 0.82 | LMNA (0.55) | LMNAMAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL2325946 | 0.80 | LMNA (0.54) | LMNAMAPTSMN1; SMN2NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| WO-2024126777-A1 | HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-01-18 | — | — | US | disclosed |
| US-20230365526-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| US-11739072-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2023-08-29 | — | — | US | disclosed |
| US-11739072-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2023-08-29 | — | — | US | disclosed |
| US-20230167093-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230159496-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-05-25 | — | — | US | disclosed |
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | SEPRACOR INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | SEPRACOR INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| US-20070010667-A1 | Preparation and use of compounds as aspartyl protease inhibitors | SCHERING CORPORATION | 2007-01-11 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| WO-2006138266-A2 | THE PREPARATION AND USE OF COMPOUNDS AS ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006065277-A2 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2006-06-22 | — | — | WO | disclosed |
| EP-0058006-B1 | IMIDAZOLINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1985-04-10 | — | — | EP | disclosed |
| EP-0058006-A1 | Imidazoline derivatives, process for the preparation thereof, pharmaceutical compositions containing them and their use | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1982-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | RBM17, HNRNPA1, HNRNPAB | LMNA 304/4885MAPT 3982/4885SMN1; SMN2 317/4885 |
| US-20230159496-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | LMNA 324/4885MAPT 3414/4885SMN1; SMN2 301/4885 |
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | CNR1, CNR2, GABRA5 | LMNA 2323/4885MAPT 1056/4885SMN1; SMN2 1946/4885 |
| US-20070010542-A1 | Benzimidazole compound | HRH2, GIPR, HRH4 | LMNA 3526/4885MAPT 4733/4885SMN1; SMN2 3159/4885 |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | LMNA 3406/4885MAPT 3370/4885SMN1; SMN2 2611/4885 |
| US-20230167093-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | LMNA 324/4885MAPT 3414/4885SMN1; SMN2 301/4885 |
| US-20230365526-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, RBM17, SNRPB2 | LMNA 214/4885MAPT 3372/4885SMN1; SMN2 395/4885 |
| US-20070010667-A1 | Preparation and use of compounds as aspartyl protease inhibitors | PRSS1, CTSS, CTSL | LMNA 1905/4885MAPT 125/4885SMN1; SMN2 1654/4885 |
| US-11739072-B2 | Heteroaryl compounds and their use | GBA1, GBA2, GAA | LMNA 127/4885MAPT 229/4885SMN1; SMN2 36/4885 |
| US-20070015782-A1 | Benzimidazole compound | HRH2, GIPR, HRH4 | LMNA 3526/4885MAPT 4733/4885SMN1; SMN2 3159/4885 |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | HNRNPAB, HNRNPC, HNRNPA1 | LMNA 430/4885MAPT 2035/4885SMN1; SMN2 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.